IDYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the investor's long-term strategy, beginner knowledge level, and available capital, IDEAYA Biosciences (IDYA) is a good buy. The stock has strong positive catalysts, favorable analyst ratings, and upcoming clinical trial data that could drive significant upside. While the financials show losses, the revenue growth and gross margin are promising for a biotech company in its growth phase.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 54.47, showing no overbought or oversold conditions. The stock is trading near its pivot level of 31.973, with resistance at 33.843 and support at 30.103. This suggests a stable price range with potential for upward movement.
Citi placed an 'upside 90-day catalyst watch' with a $65 price target, citing favorable setup for upcoming Phase 2/3 trial data.
Multiple analysts have raised price targets recently, with the highest at $
The company has initiated new clinical trials for IDE849 and IDE161, showing potential efficacy in solid tumors and small cell lung cancer.
Strong revenue growth of 55.37% YoY in Q4 2025.
Net income and EPS have significantly declined YoY, reflecting ongoing losses.
No recent insider or hedge fund buying activity, indicating neutral sentiment from key stakeholders.
In Q4 2025, revenue increased by 55.37% YoY to $10.88M, demonstrating strong growth. However, net income dropped by 36.10% YoY to -$83.27M, and EPS fell by 36.91% YoY to -0.94. Gross margin remains at 100%, which is positive for a biotech company.
Analysts are overwhelmingly positive on IDYA, with multiple Buy ratings and price targets ranging from $45 to $65. Upcoming clinical trial data in late March is seen as a key catalyst, with high probabilities of success and significant upside potential.
